Cardiol Therapeutics Statistics
Total Valuation
CRDL has a market cap or net worth of $99.38 million. The enterprise value is $88.31 million.
Important Dates
The next estimated earnings date is Monday, March 31, 2025, after market close.
| Earnings Date | Mar 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRDL has 81.60 million shares outstanding. The number of shares has increased by 5.66% in one year.
| Current Share Class | 81.60M |
| Shares Outstanding | 81.60M |
| Shares Change (YoY) | +5.66% |
| Shares Change (QoQ) | +1.59% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 77.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 12.87 |
| P/TBV Ratio | 12.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.49, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.49 |
| Quick Ratio | 2.32 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -159.53% and return on invested capital (ROIC) is -104.92%.
| Return on Equity (ROE) | -159.53% |
| Return on Assets (ROA) | -79.07% |
| Return on Invested Capital (ROIC) | -104.92% |
| Return on Capital Employed (ROCE) | -362.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.46M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.14% in the last 52 weeks. The beta is 0.67, so CRDL's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -28.14% |
| 50-Day Moving Average | 1.32 |
| 200-Day Moving Average | 1.86 |
| Relative Strength Index (RSI) | 41.61 |
| Average Volume (20 Days) | 274,837 |
Short Selling Information
The latest short interest is 1.43 million, so 1.76% of the outstanding shares have been sold short.
| Short Interest | 1.43M |
| Short Previous Month | 1.56M |
| Short % of Shares Out | 1.76% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 5.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.36M |
| Pretax Income | -21.99M |
| Net Income | -26.75M |
| EBITDA | -28.26M |
| EBIT | -28.36M |
| Earnings Per Share (EPS) | -$0.39 |
Full Income StatementBalance Sheet
The company has $11.76 million in cash and $122,865 in debt, giving a net cash position of $11.64 million or $0.14 per share.
| Cash & Cash Equivalents | 11.76M |
| Total Debt | 122,865 |
| Net Cash | 11.64M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 7.72M |
| Book Value Per Share | 0.11 |
| Working Capital | 7.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$19.20 million and capital expenditures -$19,125, giving a free cash flow of -$18.23 million.
| Operating Cash Flow | -19.20M |
| Capital Expenditures | -19,125 |
| Free Cash Flow | -18.23M |
| FCF Per Share | -$0.22 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |